Pharmasset
Setback for Gilead hep C candidate
February 20, 2012Research and Development, Sales and Marketing ELECTRON, GS-7977, Gilead, Pharmasset
Gilead’s investigational hepatitis C drug has been dealt a blow after patients suffer relapses in a mid-stage trial. In the …
Gilead aims for hep C lead with Pharmasset acquisition
November 22, 2011Research and Development Gilead, HCV, Pharmasset, Victrelis, hepatitis C
Gilead Sciences is to buy Pharmasset for $11 billion in a bid to become a leader in hepatitis C treatment.The …
Contract research news in brief
January 5, 2011Research and Development Accel Synthesis, Almac, Bioanalytical Systems, Caliper Life Sciences, Cambridge Research & Instrumentation, Critical Path Services, Pharmasset, ReSearch Pharmaceutical Services, ResourcingPoint, Warburg Pincus
Private equity firm Warburg Pincus buys RPS for $227 million, plus updates from BASi, Almac, Caliper, and Critical Path Services/Accel …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
September 25, 2026
One in three UK women with migraine say symptoms taken less seriously
September 24, 2026
Report highlights scope to expand day surgery
September 23, 2026
Sygnature formalises drug discovery collaboration with X-Chem
September 22, 2026
Codis appoints Steven Facer as chief commercial officer
September 21, 2026
